Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Ying T, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS.

J Biol Chem. 2013 Aug 30;288(35):25154-64. doi: 10.1074/jbc.M113.484154. Epub 2013 Jul 18.

2.

Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.

Wilkinson IC, Fowler SB, Machiesky L, Miller K, Hayes DB, Adib M, Her C, Borrok MJ, Tsui P, Burrell M, Corkill DJ, Witt S, Lowe DC, Webster CI.

MAbs. 2013 May-Jun;5(3):406-17. doi: 10.4161/mabs.23941. Epub 2013 Apr 8.

3.

Soluble monomeric IgG1 Fc.

Ying T, Chen W, Gong R, Feng Y, Dimitrov DS.

J Biol Chem. 2012 Jun 1;287(23):19399-408. doi: 10.1074/jbc.M112.368647. Epub 2012 Apr 19.

4.

Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.

Ying T, Wang Y, Feng Y, Prabakaran P, Gong R, Wang L, Crowder K, Dimitrov DS.

MAbs. 2015;7(5):922-30. doi: 10.1080/19420862.2015.1067353.

5.

Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.

Burvenich IJ, Farrugia W, Lee FT, Catimel B, Liu Z, Makris D, Cao D, O'Keefe GJ, Brechbiel MW, King D, Spirkoska V, Allan LC, Ramsland PA, Scott AM.

MAbs. 2016 May-Jun;8(4):775-86. doi: 10.1080/19420862.2016.1156285. Epub 2016 Mar 30.

6.

Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT.

J Immunol. 2015 Jun 1;194(11):5497-508. doi: 10.4049/jimmunol.1401218. Epub 2015 Apr 22.

7.

Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.

Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A.

MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15.

8.

Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor.

Walters BT, Jensen PF, Larraillet V, Lin K, Patapoff T, Schlothauer T, Rand KD, Zhang J.

J Biol Chem. 2016 Jan 22;291(4):1817-25. doi: 10.1074/jbc.M115.691568. Epub 2015 Dec 1.

9.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

10.

Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.

Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT.

J Control Release. 2016 Feb 10;223:42-52. doi: 10.1016/j.jconrel.2015.12.033. Epub 2015 Dec 21.

PMID:
26718855
11.

Robust expression of the human neonatal Fc receptor in a truncated soluble form and as a full-length membrane-bound protein in fusion with eGFP.

Seijsing J, Lindborg M, Löfblom J, Uhlén M, Gräslund T.

PLoS One. 2013 Nov 18;8(11):e81350. doi: 10.1371/journal.pone.0081350. eCollection 2013.

12.

Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor.

Feng Y, Gong R, Dimitrov DS.

Protein Expr Purif. 2011 Sep;79(1):66-71. doi: 10.1016/j.pep.2011.03.012. Epub 2011 Mar 29.

13.

Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.

Gong R, Wang Y, Ying T, Dimitrov DS.

PLoS One. 2012;7(8):e42288. doi: 10.1371/journal.pone.0042288. Epub 2012 Aug 7.

14.

Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.

Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, Mcgreevy W, Zheng K, Kelley RF, Laird MW, Liu J, Cromwell M.

J Pharm Sci. 2015 Feb;104(2):368-77. doi: 10.1002/jps.24136. Epub 2014 Aug 29.

PMID:
25175600
15.

Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.

Sockolosky JT, Tiffany MR, Szoka FC.

Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16095-100. doi: 10.1073/pnas.1208857109. Epub 2012 Sep 18.

16.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.

Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.

MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353.

17.

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

Dall'Acqua WF, Kiener PA, Wu H.

J Biol Chem. 2006 Aug 18;281(33):23514-24. Epub 2006 Jun 21.

18.

Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002. doi: 10.1073/pnas.1408766112. Epub 2015 Apr 27.

20.

X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Mezo AR, Sridhar V, Badger J, Sakorafas P, Nienaber V.

J Biol Chem. 2010 Sep 3;285(36):27694-701. doi: 10.1074/jbc.M110.120667. Epub 2010 Jun 30.

Supplemental Content

Support Center